Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0002199,
umls-concept:C0003241,
umls-concept:C0020861,
umls-concept:C0042776,
umls-concept:C0087111,
umls-concept:C0229671,
umls-concept:C0441889,
umls-concept:C0444669,
umls-concept:C0524910,
umls-concept:C0681842,
umls-concept:C0871261,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
pubmed:issue |
2
|
pubmed:dateCreated |
1996-10-17
|
pubmed:abstractText |
We measured the optical densities (OD) of serum anti-hepatitis C virus IgM core antibodies in 40 HCV-positive patients (24 males and 16 females) with histologically proven chronic active hepatitis but without cirrhosis. All patients were treated with i.m. injections of 3 MU thrice weekly of interferon-alpha (IFN-alpha) for 6 months and followed-up monthly. Optical densities were evaluated in thawed sera before beginning treatment and 6 months after completion, and in fresh sera obtained at the end of an 8-12-month follow-up period. Patients were grouped into three categories according to the OD obtained: < 0.3 (negative test); 0.3-0.6 (intermediate positivity); > 0.6 (high positivity). According to the response to treatment during the follow-up period, patients were further divided into three classes: sustained responders; relapsers or partial responders; non-responders. In each patient, the OD values were similar in the three determinations before, after therapy and at the end of the follow-up period. All patients with an intermediate positive test for anti-HCV IgM core antibodies were relapsers or partial responders, and all patients with high OD values were non-responders. Conversely, 71% of the patients with a negative test were sustained responders. We conclude that this cheap and easily performed test may be useful in predicting the response to IFN therapy.
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
1352-0504
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
1
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
155-7
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:8790571-Adult,
pubmed-meshheading:8790571-Chronic Disease,
pubmed-meshheading:8790571-Female,
pubmed-meshheading:8790571-Hepatitis C,
pubmed-meshheading:8790571-Hepatitis C Antibodies,
pubmed-meshheading:8790571-Humans,
pubmed-meshheading:8790571-Immunoglobulin M,
pubmed-meshheading:8790571-Interferon-alpha,
pubmed-meshheading:8790571-Male,
pubmed-meshheading:8790571-Middle Aged
|
pubmed:year |
1994
|
pubmed:articleTitle |
Serum levels of anti-hepatitis C virus IgM core antibodies may predict the response to interferon-alpha therapy in chronic hepatitis C.
|
pubmed:affiliation |
Division of Gastroenterology, Ospedale Mauriziano Umberto I di Torino, Italy.
|
pubmed:publicationType |
Journal Article
|